DUBLIN--(BUSINESS WIRE)--The "Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024" report has been added to Research and Markets' offering.
United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024
Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine.
Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024 provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an in-depth analysis of the flu vaccination pattern in both Children and Adults in the United States.
It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.
Long-term Growth Projection and Development:
- Sanofi to Acquire Protein Sciences Corporation
- It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024
- Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season
- It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024
- BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine
Major Flu Vaccines Covered Under This Report Are:
- Fluzone High-Dose
- Fluzone Quadrivalent
- Intradermal (ID) Trivalent
- Vaxigrip
- Fluarix Quadrivalent
- Flulaval Quadrivalent
- Flucelvax Quadrivalent
- Afluria Quadrivalent
- Agrippal
- Fluad
- Fluvirin
- Fluvax
Key Companies Covered in This Report:
- Seqirus
- Sanofi Pasteur
- GlaxoSmithKline (GSK)
Key Topics Covered:
1. Executive Summary
2. Market Overview: United States Flu Vaccine Market (2010 - 2024)
3. United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)
4. Key Drivers and Inhibitors of the United States Flu Vaccine Market
5. United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
6. United States Flu Vaccine Market - Reimbursement & Regulatory System
7. Market Dynamics - Mergers, Acquisitions, Key Agreements & Collaborations
8. Flu Vaccine - Promising Vaccine in Clinical Development
9. Flu Vaccine - Clinical Trial Insights by Phase, Company & Country
10. Key Companies Analysis
For more information about this report visit https://www.researchandmarkets.com/research/fvfcmt/flu_vaccine
